StockNews.AI
CMND
StockNews.AI
133 days

Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

1. CMND announced a new patent application for psychedelic-based compounds. 2. Collaboration with Yissum Research aims to innovate mental health treatments. 3. This patent strengthens CMND's portfolio in addiction and mental health. 4. CMND has 31 granted patents across 19 families. 5. Focus remains on developing safe, scalable psychedelic therapies.

7m saved
Insight
Article

FAQ

Why Bullish?

The successful patent publication may lead to commercial advancements, similar to successful biotech innovations increasing stock value.

How important is it?

The development of innovative applications in a fast-growing sector increases CMND's potential significantly, impacting future valuations positively.

Why Long Term?

Long-term effects anticipated as new treatments progress through phases and can gain regulatory approvals, creating a significant market position.

Related Companies

YISSNVIVATXI
April 08, 2025 06:55 ET  | Source: Clearmind Medicine Inc. Vancouver, Canada, April 08, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today the publication of an international patent application in collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”). The patent application covers innovative psychedelic-based compounds designed for the treatment of mental health disorders and addiction. Dr. Adi Zuloff-Shani, CEO of Clearmind, commented, “The publication highlights the potential of our collaboration with Yissum in our mission to transform mental health treatment through next-generation psychedelic-based therapeutics. Our collaboration with Yissum has yielded highly innovative compounds that go beyond the limitations of classical psychedelics. These new 3.0 compounds reflect our ongoing efforts to advancing safe, effective and scalable solutions for some of the most challenging and under-treated mental health and addiction disorders.” The patent is part of Clearmind’s exclusive worldwide licensing agreement with Yissum to develop, research, manufacture, market and commercialize products derived from a patent-pending synthesis of psychedelic compounds, enriching the company’s innovative portfolio in addiction and mental health treatments. About Clearmind Medicine Inc. Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.” For further information visit: https://www.clearmindmedicine.com or contact: Investor Relations invest@clearmindmedicine.com Telephone: (604) 260-1566 US: CMND@crescendo-ir.com General Inquiries Info@Clearmindmedicine.com www.Clearmindmedicine.com Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential of its collaboration with Yissum in its mission to transform mental health treatment through next-generation psychedelic-based therapeutics and its ongoing efforts to advancing safe, effective and scalable solutions for some of the most challenging and under-treated mental health and addiction disorders. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

Related News